We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Topical cosmetic peptide — not a dietary supplement
Matrixyl is a topical cosmetic ingredient, not a supplement you take internally and not a drug. It is sold legally in skincare products to affect the appearance of skin (such as wrinkles). The evidence below comes mostly from small, often industry-funded studies of topical application, so treat the effect sizes cautiously. This page is for transparency and education, not a recommendation.
What the evidence says
Most Matrixyl studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality randomised trials published 2004–2025.
Based on 6 studies · 3 RCTs
Confidence
ModerateBy outcome
Matrixyl has an evidence score of 3/10 — emerging evidence based on 6 indexed studies. A topical cosmetic peptide — a leave-on skincare ingredient, NOT something you swallow, inject, or take as a supplement, and NOT a drug. Matrixyl is palmitoyl pentapeptide-4 (pal-KTTKS), a fatty-acid-attached fragment of type I collagen; the popular 'Matrixyl 3000' blend pairs palmitoyl tripeptide-1 with palmitoyl tetrapeptide-7. Rather than relaxing muscle like Argireline, Matrixyl is a 'signal peptide' marketed to nudge skin fibroblasts to make more collagen and extracellular matrix. There ARE real human topical studies — most notably a 12-week, double-blind, placebo-controlled, split-face trial that found modest but significant reductions in fine-line appearance — alongside in-vitro work showing it raises collagen/ECM genes. But the human effect sizes are small, several trials are industry-linked or null, and this is a cosmetic effect on skin APPEARANCE, not a health outcome. It is generally well tolerated on skin. This entry describes a cosmetic ingredient honestly, not an ingestible supplement. Representative study: PMID 18492182.
PT-141
Mostly mechanism / observationalA melanocortin-receptor (MC4R) agonist peptide for low sexual desire. Important honest framing: unlike most 'research peptides', bremelanotide is an FDA-APPROVED prescription drug — Vyleesi, approved 2019 — for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, self-injected subcutaneously on-demand. It has real phase-3 RCTs (the RECONNECT program). The catch: the approved-trial benefit was statistically significant but small (a fraction of a point on desire scales), nausea is very common, and it transiently raises blood pressure. Grey-market 'PT-141' vials sold online are NOT the approved drug and are unregulated.
Last reviewed June 2026 · evidence from 6 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Palmitoyl Pentapeptide-4 (Matrixyl)
A topical cosmetic peptide — a leave-on skincare ingredient, NOT something you swallow, inject, or take as a supplement, and NOT a drug. Matrixyl is palmitoyl pentapeptide-4 (pal-KTTKS), a fatty-acid-attached fragment of type I collagen; the popular 'Matrixyl 3000' blend pairs palmitoyl tripeptide-1 with palmitoyl tetrapeptide-7. Rather than relaxing muscle like Argireline, Matrixyl is a 'signal peptide' marketed to nudge skin fibroblasts to make more collagen and extracellular matrix. There ARE real human topical studies — most notably a 12-week, double-blind, placebo-controlled, split-face trial that found modest but significant reductions in fine-line appearance — alongside in-vitro work showing it raises collagen/ECM genes. But the human effect sizes are small, several trials are industry-linked or null, and this is a cosmetic effect on skin APPEARANCE, not a health outcome. It is generally well tolerated on skin. This entry describes a cosmetic ingredient honestly, not an ingestible supplement.
Low Emerging score reflects a topical cosmetic peptide with only one or two small, short, industry-linked split-face trials showing modest fine-line appearance benefits, supported by in-vitro collagen data but undercut by a null human trial.
Matrixyl is the trade name for palmitoyl pentapeptide-4 (pal-KTTKS): the pentapeptide Lys-Thr-Thr-Lys-Ser — a sub-fragment of the type I procollagen molecule — conjugated to palmitic acid to improve its ability to associate with skin.
The closely related 'Matrixyl 3000' blend combines two other palmitoylated peptides, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7. All of these are TOPICAL cosmetic actives applied to the skin — none is a dietary supplement, none is ingested, and none is injected.
Unlike Argireline (which targets muscle contraction), Matrixyl is a 'matrikine' or signal peptide: the KTTKS fragment is thought to act as a feedback signal that prompts dermal fibroblasts to ramp up synthesis of collagen and other extracellular-matrix (ECM) components, in part via TGF-β-linked pathways, theoretically firming skin and softening fine lines.
The strongest human evidence is a 12-week, double-blind, placebo-controlled, split-face, left-right randomized clinical trial in 93 women (Procter & Gamble; Robinson et al., 2005): a moisturizer containing just 3 ppm pal-KTTKS produced significant improvement versus the same moisturizer alone for reduction of wrinkles/fine lines by both image analysis and expert grading, and was well tolerated.
A later double-blind randomized trial in Asian skin (Aruan et al., 2023) found palmitoyl pentapeptide-4 cream outperformed both acetyl hexapeptide-3 and placebo on crow's-feet measures, though it was small (21 subjects, 8 weeks).
The mechanistic and delivery literature is consistent: pal-KTTKS is more stable and penetrates skin layers far better than the unmodified KTTKS peptide (Choi et al., 2014, hairless-mouse skin), and in fibroblast cell studies Matrixyl up-regulates ECM-related genes such as COL1A1, FN1 and HAS1 and induces collagenesis comparable to or stronger than several experimental analogues (Paccola et al., 2025; Gomes et al., 2022).
Now the honest caveats.
The human controlled evidence is thin — essentially one or two small, short, often industry-linked split-face trials — and at least one randomized clinical comparison found no benefit: a trial of a Matrixyl-containing cream (Thêta-Cream) for radiation dermatitis in breast-cancer patients showed no advantage over standard dexpanthenol lotion and slightly more adverse events (Röper et al., 2004).
As with all topical peptides, skin penetration is the limiting factor and effects are formulation-dependent. None of this is a health claim: Matrixyl is a lawful over-the-counter cosmetic whose documented benefit is a small, cosmetic improvement in the look of fine lines and skin texture.
It is grouped here with research peptides by category convention, sandboxed out of ingestible-supplement and goal-based recommendations, and carries a cosmetic-peptide badge and a topical-only disclaimer.
The KTTKS pentapeptide in Matrixyl is a sub-fragment of type I procollagen and acts as a 'matrikine' feedback signal: applied to skin, it is proposed to prompt dermal fibroblasts to increase synthesis of collagen and other extracellular-matrix components, in part via TGF-β-linked pathways. In fibroblast cell studies it up-regulates ECM genes such as COL1A1, FN1 and HAS1.
Attaching palmitic acid to the KTTKS peptide (pal-KTTKS) makes it markedly more stable in skin and lets it reach the stratum corneum, epidermis and dermis, whereas the unmodified peptide does not penetrate. This is the rationale for the lipidated 'Matrixyl' form versus bare KTTKS.
By nudging collagen and ECM production over weeks of use, Matrixyl is proposed to improve the appearance of fine lines and skin texture/firmness. This is a cosmetic, appearance-level effect seen in small split-face trials — not a measured change in any health outcome.
How Matrixyl works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Topical cosmetic only. Matrixyl (palmitoyl pentapeptide-4 / pal-KTTKS, or the Matrixyl 3000 blend of palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7) is used at very low concentrations in leave-on serums and creams — clinical benefit was shown at as little as 3 ppm pal-KTTKS, and consumer products commonly list 3-10% of the branded blend. Applied to the target area once or twice daily. There is no oral, injectable, or systemic dose — it is not ingested.
Can be taken without food
| Form | Type |
|---|---|
| 🧴Leave-on topical cosmetic (serum or cream) containing palmitoyl pentapeptide-4 or the Matrixyl 3000 blend | Recommended |
| 🧴Penetration-enhanced or encapsulated topical formulations | Alternative |
There is no legitimate oral or injectable form. Matrixyl is a cosmetic skincare active applied to the skin surface.
Minimum: 8 weeks
Optimal: 12 weeks
Cycling: Not required
Note: Applied topically to clean skin, commonly once or twice daily. As a leave-on cosmetic there is no ingestion or meal-timing consideration.
Dose-response data unavailable. The current published research for Matrixyl does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Every documented benefit is a modest improvement in the APPEARANCE of fine lines and skin texture. Matrixyl is a topical cosmetic, not an ingested supplement or a drug; it does not treat any disease.
A 12-week double-blind, placebo-controlled, split-face trial found significant reductions in wrinkles/fine lines versus the same moisturizer alone; a small Asian-skin RCT favored it on crow's-feet. Effect sizes are modest.
In dermal-fibroblast cell studies, Matrixyl up-regulates ECM-related genes (COL1A1, FN1, HAS1) and induces collagenesis — the mechanistic basis for the appearance claims, demonstrated in cells rather than people.
Topical pal-KTTKS was well tolerated in the controlled wrinkle trials, with low irritation at the very low cosmetic-use concentrations involved.
The human controlled data come from one or two small, short, often industry-linked split-face trials; at least one randomized clinical trial of a Matrixyl cream found no benefit over standard care. Results are formulation-dependent.
As with any leave-on cosmetic, mild local irritation, redness, or contact reaction is possible, especially in sensitive skin. Patch-test before facial use.
Topical cosmetic peptides have not been formally studied in pregnancy or lactation; discuss any skincare active with a clinician. The peptide is not ingested, but evidence in these populations is absent.
Patch-test first and introduce slowly; mild irritation is the main concern with any leave-on active.
Manage expectations — the effect is a small, cosmetic improvement in the appearance of fine lines and texture, not a substitute for prescription retinoids or procedures.
Layering with strong leave-on actives (retinoids, AHAs/BHAs) may increase local irritation in some people. This is a formulation/tolerance consideration, not a systemic drug interaction — Matrixyl is not ingested.
Tip: Patch-test before facial use; reduce frequency or discontinue if irritation occurs.
Tip: Discontinue and avoid if an allergic reaction occurs; choose a fragrance-free formulation. A radiation-dermatitis trial of a Matrixyl-containing cream noted occasional irritation/allergic reactions.
The commonly studied dose of Matrixyl is Topical cosmetic only. Matrixyl (palmitoyl pentapeptide-4 / pal-KTTKS, or the Matrixyl 3000 blend of palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7) is used at very low concentrations in leave-on serums and creams — clinical benefit was shown at as little as 3 ppm pal-KTTKS, and consumer products commonly list 3-10% of the branded blend. Applied to the target area once or twice daily. There is no oral, injectable, or systemic dose — it is not ingested.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Matrixyl — consistent daily use matters more than the time of day. Matrixyl is a leave-on topical cosmetic, not an ingested supplement — there is no meal-timing relationship.
Matrixyl is generally well-tolerated and considered safe for most healthy adults at recommended doses. The most commonly reported side effects are local skin irritation or redness, contact allergic reaction. Use caution if any of these apply to you: For topical (skin) use only — not for ingestion, not for injection; Known allergy or sensitivity to the peptide or formulation excipients; Application to broken, irritated, or compromised skin until healed.
Gonadorelin
Mostly mechanism / observationalA synthetic copy of gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pituitary to release LH and FSH. Honest appraisal: it has genuine, trial-backed roles as a diagnostic agent (the GnRH/gonadorelin stimulation test) and — delivered in pulses by an infusion pump — for inducing ovulation in hypothalamic amenorrhea and spermatogenesis in men with congenital hypogonadotropic hypogonadism. Its now-trendy use in men's TRT clinics (compounded, to 'maintain testosterone/fertility' alongside testosterone, often replacing hCG) is largely off-label and has NOT been validated in controlled trials for that purpose.